InpharmD™





Add Drug Information Pharmacists

Without Adding FTEs

So you can practice at top of license.

Get Started Free

Trusted by 20,000+ clinical pharmacists.

Play Circle

Learn about InpharmD™ in under 90 seconds

What is InpharmD™?


Literature searching is tedious. InpharmD™ is here to help.

Clinical pharmacists can ask any question, anytime, from anywhere, and we’ll perform a custom literature search.

(And a 32% chance it’s already been asked.)


More than 30 of the world's best health systems hire an InpharmD™ virtual DI pharmacist, yielding:


167,888

Clinical Pharmacist Hours Saved

4x +

ROI

100%

Customer Satisfaction Rate

This is how InpharmD™ transforms LITERATURE.

What's Being Asked...

Is there evidence for use of tebipenem in non-UTI indications?
Please review literature for incidence of bloodstream infections in oncology patients on TPN and data comparing infec...
review literature on pembrolizumab induced diabetes (type 1) include incidence, onset of action, prevention, and phar...
Is there evidence to support the use of extended infusion beta lactams for CNS infections?
Summarize recommendations for aspirin use for primary ASCVD prophylaxis.

What would you like to ask InpharmD™?

InpharmD's Answer GPT's Answer

Author:Melissa Santibañez, PharmD, BCPS + InpharmD™ AI LEARN MORE 

Limited evidence is available regarding tebipenem for non-urinary tract infections, with most clinical efficacy data involving the Japanese tebipenem pivoxil formulation (Orapenem). Clinical studies evaluating this formulation reported favorable outcomes in pediatric respiratory and otolaryngological infections and adult otolaryngological infections, including an overall clinical efficacy rate of 94.0% in pediatric patients with pneumonia, otitis media, or sinusitis. For the U.S. tebipenem pi...

A 2025 narrative review evaluated the antimicrobial activity, pharmacokinetics/pharmacodynamics, and clinical applications of oral penems and carbapenems, including tebipenem, for bacterial infections. For nonurinary indications, the review described clinical experience with tebipenem in pediatric respiratory tract infections using the Japanese formulation and pharmacokinetic studies demonstrating pulmonary epithelial lining fluid penetration and soft-tissue penetration in patients with diabetic foot infections using the U.S.-developed tebipenem pivoxil hydrobromide formulation. The authors also identified potential applications in intra-abdominal infections based on tebipenem's broad Gram-negative and anaerobic activity, although clinical trials evaluating its efficacy for this indication were lacking. [1]

READ MORE→

A search of the published medical literature revealed 5 studies investigating the researchable question:

Is there evidence for use of tebipenem in non-UTI indications?

Level of evidence
B - One high-quality study or multiple studies with limitations  

READ MORE→

[1] Sayood S, Neuner E, Dumm R, Gandra S. The oral penems and carbapenems. Clin Microbiol Rev. 2025;38(4):e0004224. doi:10.1128/cmr.00042-24

InpharmD's Answer GPT's Answer

Author:Kevin Shin, PharmD, BCPS + InpharmD™ AI LEARN MORE 

In oncology patients receiving TPN/HPN, reported bloodstream infection incidence varies widely between stides. Several studies associate PN with increased catheter-related infection risk, but a hematologic malignancy study found no CLABSI association after adjustment. Among catheter routes, HPN data show potentially lower CRBSI with PICCs and ports than Hohn/tunneled catheters, but no direct enteral-versus-parenteral infection-rate comparisons were identified.

A search of the published medical literature revealed 7 studies investigating the researchable question:

Please review literature for incidence of bloodstream infections in oncology patients on TPN and data comparing infection rates with different routes of alimentation.

Level of evidence
C - Multiple studies with limitations or conflicting results  

READ MORE→

InpharmD's Answer GPT's Answer

Author:Naveed Aijaz, PharmD, BCPS + InpharmD™ AI LEARN MORE 

The exact incidence of pembrolizumab-induced type 1 diabetes mellitus varies; expert consensus estimates the overall incidence of immune checkpoint inhibitor–associated diabetes mellitus (CIADM) at approximately 0.4 to 1.0%. However, according to one small retrospective review, ICI-induced diabetes occurred more frequently with pembrolizumab (2.2%) when compared with nivolumab (1%) and ipilimumab (0%) Observational data often suggest an association with programmed death-1 (PD-1)/programmed de...

Guidelines published by the American Society of Clinical Oncology address management of immune-related adverse events in patients treated with immune checkpoint inhibitors, including autoimmune diabetes resulting from pembrolizumab toxicity. The guidelines emphasize early recognition of abrupt insulin deficiency and diabetic ketoacidosis (DKA), but do not specifically note any evidence of preventive medications. The discussed management recommendations largely reflect expert consensus. Patients developing new cases of polyuria, polydipsia, weight loss, or lethargy should undergo prompt assessment of glucose, electrolytes, anion gap, ketones, and acid-base status, with C-peptide, insulin, and pancreatic autoantibodies obtained to support diagnosis without delaying treatment. When autoimmune diabetes is suspected, insulin initiation and urgent endocrinology consultation are recommended, with hospitalization appropriate if timely outpatient management is unavailable, even without estab...

READ MORE→

A search of the published medical literature revealed 4 studies investigating the researchable question:

Please provide an overview of pembrolizumab-induced diabetes type 1.

Level of evidence
C - Multiple studies with limitations or conflicting results  

READ MORE→

[1] Chitnis SD, Mortazavi A. Clinical guideline highlights for the hospitalist: Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy. J Hosp Med. 2023;18(11):1013-1016. doi:10.1002/jhm.13097
[2] Wu L, Tsang V, Clifton-Bligh R, et al. Hyperglycemia in patients treated with immune checkpoint inhibitors: key clinical challenges and multidisciplinary consensus recommendations. J Immunother Cancer. 2025;13(6):e011271. Published 2025 Jun 8. doi:10.1136/jitc-2024-011271
[3] Hu Q, Fan Y, He P. Islet function impairment outcomes of immune checkpoint inhibitors in cancer patients: a systematic review and meta-analysis. Front Immunol. 2026;17:1669492. Published 2026 Mar 19. doi:10.3389/fimmu.2026.1669492
[4] Chen B, Liu J, Gan K, et al. A network meta-analysis of endocrine adverse events induced by immune checkpoint inhibitors in colorectal cancer. Front Immunol. 2026;17:1798732. Published 2026 Jul 10. doi:10.3389/fimmu.2026.1798732
[5] de Filette J, Andreescu CE, Cools F, Bravenboer B, Velkeniers B. A Systematic Review and Meta-Analysis of Endocrine-Related Adverse Events Associated with Immune Checkpoint Inhibitors. Horm Metab Res. 2019;51(3):145-156. doi:10.1055/a-0843-3366
[6] Cheng R, Boparai M, Zhu X, Wu S. Increased Risk of Hyperglycemia in Advanced Urothelial Cancer Patients Treated with Enfortumab Vedotin: A Systematic Review and Meta-Analysis. Cancer Invest. 2025;43(5):293-304. doi:10.1080/07357907.2025.2502992

InpharmD's Answer GPT's Answer

Author:Frances Beckett-Ansa, PharmD, BCPS + InpharmD™ AI LEARN MORE 

Available evidence supporting extended- or continuous-infusion beta-lactams for central nervous system (CNS) infections remains limited, with insufficient high-quality data demonstrating improved clinical outcomes compared with intermittent infusion. The 2017 Infectious Diseases Society of America (IDSA) guidelines suggest that prolonged meropenem infusion over 3 hours may be effective against resistant Gram-negative organisms in healthcare-associated ventriculitis and meningitis, although th...

The 2017 Infectious Diseases Society of America (IDSA) clinical practice guidelines for healthcare-associated ventriculitis and meningitis recommend vancomycin in combination with an antipseudomonal beta-lactam (cefepime, ceftazidime, or meropenem) for empiric treatment, with antibiotic selection guided by local susceptibility patterns (strong recommendation, low-quality evidence). For infections caused by Gram-negative bacilli, the guidelines recommend selecting agents based on susceptibility testing and adequate central nervous system (CNS) penetration (strong recommendation, moderate-quality evidence). Notably, the guidelines state that prolonged infusion of meropenem, administered over 3 hours per dose, may be successful in treating resistant Gram-negative organisms (weak recommendation, low-quality evidence). The supporting evidence indicates that extended (≥3-hour) or continuous infusions of carbapenems and piperacillin/tazobactam have been associated with improved clinical ou...

READ MORE→

A search of the published medical literature revealed 4 studies investigating the researchable question:

Is there evidence to support the use of extended infusion beta lactams for CNS infections?

Level of evidence
C - Multiple studies with limitations or conflicting results  

READ MORE→

[1] Tunkel AR, Hasbun R, Bhimraj A, et al. 2017 Infectious Diseases Society of America’s clinical practice guidelines for healthcare-associated ventriculitis and meningitis. Clin Infect Dis. 2017;64(6):e34-e65. doi:10.1093/cid/ciw861
[2] Hong LT, Downes KJ, FakhriRavari A, et al. International consensus recommendations for the use of prolonged-infusion beta-lactam antibiotics: endorsed by the American College of Clinical Pharmacy, British Society for Antimicrobial Chemotherapy, Cystic Fibrosis Foundation, European Society of Clinical Microbiology and Infectious Diseases, Infectious Diseases Society of America, Society of Critical Care Medicine, and Society of Infectious Diseases Pharmacists. Pharmacotherapy. 2023;43(8):740-777. doi:10.1002/phar.2842
[3] Kumta N, Roberts JA, Lipman J, Wong WT, Joynt GM, Cotta MO. A systematic review of studies reporting antibiotic pharmacokinetic data in the cerebrospinal fluid of critically ill patients with uninflamed meninges. Antimicrob Agents Chemother. 2021;65(1):e01998-20. doi:10.1128/AAC.01998-20
[4] Karvouniaris M, Brotis A, Tsiakos K, Palli E, Koulenti D. Current perspectives on the diagnosis and management of healthcare-associated ventriculitis and meningitis. Infect Drug Resist. 2022;15:697-721. doi:10.2147/IDR.S326456

InpharmD's Answer GPT's Answer

Author:Neil Patel, PharmD, BCPS + InpharmD™ AI LEARN MORE 

Based on the most recent guidelines, routine aspirin is not universally recommended for primary atherosclerotic cardiovascular disease (ASCVD) prevention based on its modest cardiovascular benefit, which is offset by increased risk of bleeding. Instead, the guidance incorporates nuance into applicable recommendations. The U.S. Preventive Services Task Force supports individualized initiation at ages 40-59 years with ≥10% 10-year cardiovascular risk (Grade C) and recommends against initiation ...

The most recent 2026 American College of Cardiology scientific statement recommends that low-dose aspirin may be considered for primary ASCVD prevention in selected adults aged 40-70 years who have higher cardiovascular risk without increased bleeding risk. Routine use in adults older than 70 years should be avoided, and aspirin is associated with net harm in patients with high bleeding risk regardless of ASCVD risk or coronary artery calcium (CAC) score. Cardiovascular risk calculators, including the Pooled Cohort Equations and PREVENT equations, may help identify potential candidates. Of note, these are consensus recommendations without a specific level of evidence attributed to them. [1] Supporting evidence cited in the statement includes a meta-analysis of 13 trials involving 165,265 participants in which aspirin modestly reduced cardiovascular events (HR 0.89) but increased major bleeding (HR 1.43), including gastrointestinal bleeding (HR 1.56) and intracranial bleeding (HR ...

READ MORE→

A search of the published medical literature revealed 5 studies investigating the researchable question:

What are recommendations for aspirin use for primary ASCVD prophylaxis?

Level of evidence
B - One high-quality study or multiple studies with limitations  

READ MORE→

[1] Kumbhani DJ, Gibson CM, Kinlay S, et al. Antiplatelet Therapy in the Management of Atherosclerotic Cardiovascular Disease: 2026 ACC Scientific Statement: A Report of the American College of Cardiology. J Am Coll Cardiol. 2026;88(11):1284-1313. doi:10.1016/j.jacc.2026.05.037
[2] American Diabetes Association Professional Practice Committee for Diabetes*. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2026. Diabetes Care. 2026;49(Suppl 1):S216-S245. doi:10.2337/dc26-S010
[3] US Preventive Services Task Force. Aspirin use to prevent cardiovascular disease: US Preventive Services Task Force recommendation statement. JAMA. 2022;327(16):1577-1584. doi:10.1001/jama.2022.4983. JAMA Network

Why choose InpharmD™?

Find answers, not documents.

Before InpharmD™


BeforeTime
Your team spends hours per week cobbling together literature from different studies, many behind paywalls, leaving little time for action.
BeforeTime
TI opportunities are discovered (or presented by third parties) months after the fact, resulting in costly missed savings.
BeforeTime
Decisions may be made without a complete picture, or pushed out while gathering consensus.

After InpharmD™


BeforeTime
InpharmD™ delivers customized, actionable drug information in real time, so you can focus on execution.
BeforeTime
Your team stays informed immediately when new data emerges or prices change, and you’ll always be the first to know when any changes impact your formulary.
BeforeTime
With InpharmD™, your team can make faster, more informed decisions and move forward with confidence.

What Clinical Pharmacists Are Saying...


     

Assists in our research and is a great way or us to get an answer to a medical question without spending an average of 2 hours researching UptoDate or PubMed ourselves.


—   Jordan C., PharmD, New Jersey

     

Huge time saver with thorough responses.


—   Jane D., PharmD, Georgia

     

I’d never heard of a DI pharmacist before, now I have one. In. My. Pocket. Amazing!


     

Holy Shhh. Cow! Holy Cow! These summaries are beautiful.


—   Jane D., PharmD, Georgia

     

I just want to say: This is such a brilliant idea! You people are genius.


     

OH MY GOD WHERE HAVE YOU BEEN ALL MY LIFE!


     

I can’t tell you how much time I spend literature searching. And how I CANNOT STAND PAYWALLS. THIS IS UNBELIEVABLE!! (covers face for sec) thank you, thank you, thank you!


     

So they’re basically connecting academic researchers with front line providers and then automating everything. It’s simply brilliant.


     

The clinical pharmacist was our secret weapon anyway. (Smiles wryly) This pharmacist AI seems superhuman. I’m just blown away, honestly. (Looks at camera somberly.)


     

It’s an ENTIRE DI DEPARTMENT, that lives in Epic. Give me a second. I’m just having a hard time wrapping my head around that.


     

Sorry just give me a second, my mind is blown.


     

Stop reading and just download the app already! I’ve tried all of them. This is by far the most advanced, best-in-class.


What would you like to ask InpharmD™?

Sign up for a free trial & start right away.

Get Started Free